[en] Lipoprotein-associated phospholipase A₂ (Lp-PLA₂) is a crucial enzyme in atherosclerosis as a potential drug target. The most remarkable Lp-PLA₂ inhibitory drug is Darapladib. We determined the binding pose of Darapladib to Lp-PLA₂ through docking study. Darapladib formed two hydrogen bonding interactions with the side chain of Tyr160 and Gln352 and several pi-pi interactions with aromatic and aliphatic hydrophobic residues of Lp-PLA₂. It is known that the dietylpropan-amine moiety of Darapladib has influence on the improvement of its oral bioavailability and we supposed this in our docking results